Solid Biosciences Inc.
SLDB
$6.83
-$0.01-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -67.94% | -- | |||
| Gross Profit | 67.94% | -- | |||
| SG&A Expenses | 0.13% | 16.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.39% | 13.40% | |||
| Operating Income | -0.39% | -13.40% | |||
| Income Before Tax | 7.78% | -30.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.78% | -30.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.78% | -30.17% | |||
| EBIT | -0.39% | -13.40% | |||
| EBITDA | -0.60% | -13.32% | |||
| EPS Basic | 40.64% | -26.32% | |||
| Normalized Basic EPS | 40.63% | -26.32% | |||
| EPS Diluted | 40.64% | -26.32% | |||
| Normalized Diluted EPS | 40.63% | -26.32% | |||
| Average Basic Shares Outstanding | 55.34% | 3.05% | |||
| Average Diluted Shares Outstanding | 55.34% | 3.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||